Revolutionary Non-Invasive Treatment Shows Promise
Recent clinical findings presented at the Korean Society of Brain Neuromodulation Therapy Winter Conference reveal groundbreaking advancements in treating normal pressure hydrocephalus (NPH) through ultrasound technology. Professor Kim Jae-ho from Hallym University Dongtan Sacred Heart Hospital shared remarkable results that could transform treatment approaches for this treatable form of dementia.
Clinical Trial Details and Methodology
The exploratory trial, conducted between July 2024 and February 2025, utilized Deepson Bio’s NEUCLARE therapeutic ultrasound device specifically designed for neurological applications. Ten NPH patients participated in the study, receiving three ultrasound stimulation sessions aimed at enhancing cerebrospinal fluid (CSF) circulation.
Significant Mobility Improvements Documented
Researchers assessed participants’ mobility using two standardized tests:
- Timed Up and Go (TUG): Average decrease of 7.1 seconds (23.3% improvement)
- 10-meter walk test: Average decrease of 5.9 seconds (21.0% improvement)
Both results exceeded the clinically significant threshold of 5 seconds, demonstrating meaningful functional improvement in these patients.
Alternative to Traditional Invasive Procedures
NPH typically presents with gait disturbances, cognitive impairment, and urinary incontinence due to disrupted CSF circulation. While shunt surgery remains the standard treatment, it carries inherent risks and potential complications. This ultrasound approach offers a promising non-invasive alternative that addresses the growing demand for safer treatment options.
Future Research and Applications
Professor Kim expressed optimism about the therapy’s potential: “Enhancing cerebrospinal fluid circulation through ultrasound stimulation could serve as a groundbreaking therapeutic option for patients with normal pressure hydrocephalus.”
Deepson Bio CEO Lee Dong-hyuk highlighted broader implications: “The core mechanism underlying this study is the enhancement of cerebrospinal fluid flow to promote the clearance of brain waste. This approach has opened new possibilities for the treatment of Alzheimer’s disease by facilitating the removal of waste, such as beta-amyloid.”
Based on these promising results, plans are underway to accelerate pivotal clinical trials for both NPH and Alzheimer’s disease, potentially revolutionizing neurological treatment approaches.
Discover the latest Provider news updates with a single click. Follow DistilINFO HospitalIT and stay ahead with updates. Join our community today!
Leave a Reply